Larimar Therapeutics (LRMR) Net Income towards Common Stockholders: 2013-2020
Historic Net Income towards Common Stockholders for Larimar Therapeutics (LRMR) over the last 6 years, with Mar 2020 value amounting to -$3.6 million.
- Larimar Therapeutics' Net Income towards Common Stockholders rose 72.55% to -$3.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$35.9 million, marking a year-over-year increase of 38.68%. This contributed to the annual value of -$45.4 million for FY2019, which is 25.68% up from last year.
- According to the latest figures from Q1 2020, Larimar Therapeutics' Net Income towards Common Stockholders is -$3.6 million, which was up 50.66% from -$7.3 million recorded in Q4 2019.
- Larimar Therapeutics' 5-year Net Income towards Common Stockholders high stood at -$3.6 million for Q1 2020, and its period low was -$17.7 million during Q1 2016.
- In the last 3 years, Larimar Therapeutics' Net Income towards Common Stockholders had a median value of -$13.1 million in 2019 and averaged -$12.3 million.
- Per our database at Business Quant, Larimar Therapeutics' Net Income towards Common Stockholders plummeted by 31.65% in 2016 and then surged by 72.55% in 2020.
- Quarterly analysis of 5 years shows Larimar Therapeutics' Net Income towards Common Stockholders stood at -$10.4 million in 2016, then decreased by 25.35% to -$13.1 million in 2017, then decreased by 11.35% to -$14.6 million in 2018, then spiked by 49.84% to -$7.3 million in 2019, then spiked by 72.55% to -$3.6 million in 2020.
- Its last three reported values are -$3.6 million in Q1 2020, -$7.3 million for Q4 2019, and -$12.9 million during Q3 2019.